An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2016
At a glance
- Drugs Lenvatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 07 Jun 2017 Biomarkers information updated
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 Mar 2015 According to MD Anderson record the status is terminated. According to CT.gov record it is active, no longer recruiting. The profile reflects CT.gov record because MD Anderson displays centre specific status.